Replimune Group Inc.’s shares reached a 52-week high of $15.72 on Tuesday, extending a year-long rally that has pushed the biotech’s valuation to $1.47 billion.
The stock, which last traded at $15.69, has gained 174.3% over the past 12 months, outpacing broader biotechnology benchmarks. The advance follows upgrades from multiple analysts, citing progress on the company’s lead product and regulatory developments.
Wedbush upgraded Replimune to Outperform from Neutral, raising its price target to $19 from a prior level. Leerink similarly upgraded the stock to Outperform with a $17 target, while Cantor Fitzgerald maintained an Overweight rating. Analysts highlighted confidence in the FDA approval pathway for RP-1 in combination with nivolumab for advanced melanoma.
Replimune’s TUDRIQEV, the first oncolytic virus approved in combination with a checkpoint inhibitor for the treatment of advanced melanoma, received regulatory clearance earlier this year. The drug’s commercial launch and clinical data updates have been cited as key drivers of investor optimism.
Options activity suggests potential volatility ahead of the company’s next earnings release, with implied moves of 5.6% anticipated. InvestingPro data indicates the stock is trading near its 52-week peak with elevated price volatility, and its Fair Value assessment flags potential overvaluation at current levels.
